FDA decisions on Byetta expected in Q1

01/12/2009 | CNNMoney

The FDA may hand down this quarter its decision on a once-weekly formulation of Amylin Pharmaceuticals' Byetta as well updated labeling for the diabetes drug, CEO Daniel Bradbury said. The label changes were prompted by concerns about the risk of pancreatitis.

View Full Article in:

CNNMoney

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX
Associate Director, Compliance Business Partner I
Boehringer Ingelheim
Ridgefield, CT